Isaac E. Ciechanover Sells 7,800 Shares of Atara Biotherapeutics Inc (ATRA) Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $37.43, for a total transaction of $291,954.00. Following the sale, the chief executive officer now owns 812,613 shares in the company, valued at $30,416,104.59. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

NASDAQ:ATRA traded up $0.50 on Friday, reaching $40.95. The stock had a trading volume of 373,800 shares, compared to its average volume of 731,218. The firm has a market cap of $1.81 billion, a PE ratio of -10.21 and a beta of 2.55. Atara Biotherapeutics Inc has a 1-year low of $12.65 and a 1-year high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported ($1.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.17). analysts expect that Atara Biotherapeutics Inc will post -4.58 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wisconsin Investment Board raised its stake in shares of Atara Biotherapeutics by 53.9% in the second quarter. State of Wisconsin Investment Board now owns 41,400 shares of the biotechnology company’s stock worth $1,521,000 after acquiring an additional 14,500 shares during the last quarter. Highland Private Wealth Management bought a new position in shares of Atara Biotherapeutics in the second quarter worth about $202,000. California Public Employees Retirement System bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $2,203,000. University of Notre Dame DU Lac bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $2,073,000. Finally, Wasatch Advisors Inc. bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $395,000.

ATRA has been the topic of several recent research reports. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 target price on shares of Atara Biotherapeutics in a research report on Friday, August 3rd. Canaccord Genuity restated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, May 8th. BidaskClub lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 8th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 6th. Finally, Citigroup reduced their price target on shares of Atara Biotherapeutics from $25.00 to $23.00 and set a “sell” rating on the stock in a research report on Monday, June 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $43.17.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Average Daily Trade Volume – ADTV

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply